Baker McKenzie and Clifford in the Minoryx – Neuraxpharm agreement

Baker McKenzie client Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system disorders (CNS), and the Neuraxpharm Group, a leading European specialty pharmaceutical company focused on CNS therapies, announced the completion of a strategic license agreement for the European rights to leriglitazone, a novel, brain penetrant and selective PPAR gamma agonist.

Under the agreement, Minoryx will receive from Neuraxpharm a significant double-digit upfront payment in addition to milestone payments and development funding totaling up to EUR 258 million in the aggregate. Minoryx will also receive material tiered double-digit royalties.

Led by Corporate Partner Randall Sunberg (Princeton / New York), the Baker McKenzie Madrid team acting on the matter involved for corporate aspects Carlos Martin, for IP Maria Dolores Garayalde and Ruben Cano and for international commercial & trade: Cecilia Pastor.

Clifford Chance has advised the Neuraxpharm Group with partner Guillermo Guardia and associate Aina Gómez.

Baker McKenzie and Clifford in the Minoryx – Neuraxpharm agreement

Ilaria

iberianlawyer.com

Iberian Lawyer, is a monthly digital magazine, published by LC Publishing, available in Spanish and English. It represents the main source of information in the legal business sector in Spain and Portugal. The digital magazine – and its portal – address to the protagonists of law firms and in-house lawyers. The magazine is available for free on the website and on Google Play and App Store.

In every issue of the magazine, you will find rankings of lawyers, special report on trends, interviews, information about deals and their advisors.

For further information, please visit the Group’s website www.lcpublishinggroup.com

Iberian Lawyer
Registered office: C/ Manuel Silvela, 8 - Oficinas 1 Dcha 28010 Madrid España

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio

SHARE

Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram